Quest Diagnostics (DGX) CFO reports stock award and tax share disposition

Rhea-AI Filing Summary

Quest Diagnostics Executive Vice President & CFO Sam Samad reported two stock transactions involving the company’s common stock. On a performance stock award settlement, he acquired 13,947 shares at $204.86 per share, increasing his direct holdings to 40,988 shares.

On the same date, 7,720 shares were disposed of at $204.86 per share, delivered back to Quest Diagnostics solely to cover tax withholding obligations related to that performance share award, leaving him with 33,268 directly owned shares after the tax-related disposition.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

SAMAD SAM

(Last) (First) (Middle)

500 PLAZA DRIVE

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Executive Vice President & CFO

3. Date of Earliest Transaction (Month/Day/Year)
03/04/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/04/2026		A		13,947(1)	A	$204.86	40,988	D
Common Stock	03/04/2026		F		7,720(2)	D	$204.86	33,268	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Stock issued by Quest Diagnostics Incorporated in settlement of a performance stock award approved in accordance with the requirements of Rule 16b-3(d).

2. Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award.

Remarks:

	Sean D. Mersten, Attorney in Fact for Sam Samad	03/06/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Quest Diagnostics (DGX) CFO Sam Samad report?

Sam Samad reported a stock award settlement and a related tax share disposition. He received 13,947 Quest Diagnostics common shares, then transferred 7,720 shares back to the company solely to cover tax withholding obligations from that performance share award.

How many Quest Diagnostics (DGX) shares did the CFO acquire in the latest Form 4?

Sam Samad acquired 13,947 shares of Quest Diagnostics common stock. These shares were issued in settlement of a performance stock award approved under Rule 16b-3(d), reflecting equity-based compensation rather than an open-market purchase of shares.

Why did the Quest Diagnostics (DGX) CFO dispose of 7,720 shares?

The 7,720 Quest Diagnostics shares were disposed of solely to cover tax withholding obligations. They were delivered back to the issuer in connection with the settlement of the same performance share award, rather than sold in an open-market transaction.

What is Sam Samad’s Quest Diagnostics (DGX) share ownership after these transactions?

After the performance stock award settlement and related tax share disposition, Sam Samad directly owns 33,268 Quest Diagnostics common shares. This figure reflects the net position following receipt of 13,947 shares and delivery of 7,720 shares for tax withholding.

At what price were the Quest Diagnostics (DGX) insider transactions recorded?

Both the acquisition and tax-related disposition were recorded at $204.86 per Quest Diagnostics share. This price applies to the 13,947-share performance award settlement and the 7,720 shares delivered back to the company for associated tax withholding obligations.